In this section of the General Tradeshow News Site, you'll find event-related news releases from PR Newswire. The releases are listed in chronological order and are archived by month and year.
First of its kind, two-year, 200-patient NEXT-2 trial utilized Guardant360 testing for therapy selection, and studied clinical response rates across multiple cancer types, including lung, gastric, melanoma, and rare cancers
Game-changing MALDI PharmaPulse (MPP) Solution Enables Mass Spectrometry-based Label-Free Ultra-High Throughput Screening for Primary Screens on Millions of Compounds in Drug Discovery
Unique Trapped Ion Mobility Spectrometry (TIMS) Coupled to Bruker's High-Performance QTOF Mass Spectrometry Enables High-Resolution Compound Separation, Significant Duty Cycle Enhancements and Studies of Protein Conformations, Aggregation and Structural Isomers